secwatch.observer — SEC 8-K summary
======================================

Issuer:     TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
CIK:        0000818686
Form:       8-K
Filed at:   2026-07-29T11:00:20+00:00
Accession:  0001171843-26-004974
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Teva Q2 revenues $4.1B, GAAP loss $0.49/share; raises 2026 outlook for key innovative brands
--------------------------------------------------------------------------------

- Q2 revenues $4.1B (-1% YoY); GAAP loss per share $0.49; non-GAAP diluted EPS $0.02 (includes $0.61 Emalex impact).
- Key innovative brands (AUSTEDO, AJOVY, UZEDY) grew 43% YoY LC to >$1B; 2026 revenue outlook raised to ~$3.7B combined.
- Acquired Emalex for ~$700M cash; NDA for ecopipam (Tourette) submitted; $726M expenses in Q2.
- Generics revenues down 15% YoY LC due to lenalidomide competition; biosimilars on track for $800M by 2027.
- ADS program replaced with ordinary shares on NYSE starting Sept 14, 2026; Fitch upgraded to BBB-.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818686/000117184326004974/0001171843-26-004974-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818686/000117184326004974/f8k_072926.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-004974

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer